BMS-284756 (T-3811ME) a new fluoroquinolone: In vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue 5, 2001, Pages 667-675

  Edelstein, Paul H ^a,b   Shinzato, Takashi ^a   Edelstein, Martha A C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN; GARENOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG EFFICACY; DRUG HALF LIFE; EXTRACELLULAR SPACE; GUINEA PIG; HUMAN; IN VITRO STUDY; LEGIONELLA PNEUMOPHILA; LEGIONNAIRE DISEASE; LUNG ALVEOLUS MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; SURVIVAL;

EID: 0035177930     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/48.5.667     Document Type: Article

References (22)

1. The in vitro activity of the novel des-(6) fluoroquinolone BMS-284756 against Gram-positive and Gram-negative aerobic bacteria
2. The in vitro activity of the novel des-(6) fluoroquinolone BMS-284756 against anaerobes, Mycoplasma, Ureaplasma, Chlamydia, and Mycobacterium spp
3. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone
4. In vitro susceptibility study of BMS-284756 against Legionella spp
5. Efficacy of BMS-284756 (T-3811ME), a des-F(6)-quinolone, against experimental pneumonia in guinea pig caused by Legionella pneumophila
6. WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages
7. In vitro activity of Ro 23-9424 against clinical isolates of Legionella species
8. In vitro activity of RP 74501-RP 74502, a novel streptogramin antimicrobial mixture, against clinical isolates of Legionella species
9. Activity of trovafloxacin (cp-99,219) against Legionella isolates: In-vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea-pig with L pneumophila pneumonia
10. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia
11. The guinea-pig model of Legionnaires disease
12. Antimicrobial chemotherapy for legionnaires' disease: A review
13. Antimicrobial therapy of experimentally induced Legionnaires' disease in guinea pigs
14. Comparison of three buffers used in the formulation of buffered charcoal yeast extract medium
15. In-vitro activity of levofloxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia
16. In vitro activity of azithromycin against clinical isolates of Legionella species
17. In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia
18. Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages
19. Safety, tolerability, and pharmacokinetics of BMS-284756, a novel des-F(6)-quinolone antibiotic, following single oral doses in healthy adult subjects
20. In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia
21. Azithromycin impact on neutrophil oxidative metabolism depends on exposure time
22. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes